DK0866720T3 - OB-protein til forögelse af mager kropsmasse - Google Patents

OB-protein til forögelse af mager kropsmasse

Info

Publication number
DK0866720T3
DK0866720T3 DK96938773T DK96938773T DK0866720T3 DK 0866720 T3 DK0866720 T3 DK 0866720T3 DK 96938773 T DK96938773 T DK 96938773T DK 96938773 T DK96938773 T DK 96938773T DK 0866720 T3 DK0866720 T3 DK 0866720T3
Authority
DK
Denmark
Prior art keywords
protein
body mass
lean body
increasing lean
increasing
Prior art date
Application number
DK96938773T
Other languages
Danish (da)
English (en)
Inventor
Christopher Francis Toombs
Mary Ann Pelleymounter
Michael Benjamin Mann
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of DK0866720T3 publication Critical patent/DK0866720T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK96938773T 1995-11-22 1996-11-04 OB-protein til forögelse af mager kropsmasse DK0866720T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56173295A 1995-11-22 1995-11-22
PCT/US1996/017718 WO1997018833A1 (en) 1995-11-22 1996-11-04 Methods of increasing lean tissue mass using ob protein compositions

Publications (1)

Publication Number Publication Date
DK0866720T3 true DK0866720T3 (da) 2004-06-14

Family

ID=24243198

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96938773T DK0866720T3 (da) 1995-11-22 1996-11-04 OB-protein til forögelse af mager kropsmasse

Country Status (15)

Country Link
EP (3) EP1285664B1 (enExample)
JP (2) JP4173914B2 (enExample)
AT (2) ATE259243T1 (enExample)
AU (3) AU7607496A (enExample)
CA (2) CA2236163A1 (enExample)
DE (2) DE69638119D1 (enExample)
DK (1) DK0866720T3 (enExample)
ES (2) ES2217327T3 (enExample)
IL (2) IL124442A0 (enExample)
MX (1) MX9803992A (enExample)
NZ (3) NZ511617A (enExample)
PT (1) PT866720E (enExample)
SI (1) SI0866720T1 (enExample)
WO (1) WO1997018833A1 (enExample)
ZA (1) ZA969605B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001968A (en) * 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
PT866720E (pt) * 1995-11-22 2004-06-30 Amgen Inc Proteina ob para aumentar a massa do tecido mole
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
EP0877627A1 (en) * 1996-01-25 1998-11-18 Eli Lilly And Company Obesity protein analog compounds and formulations thereof
AU2810497A (en) * 1996-04-19 1997-11-12 University Of Washington Methods for inducing bone formation
CA2275183A1 (en) * 1996-12-20 1998-07-02 Amgen Inc. Ob fusion protein compositions and methods
CA2274799A1 (en) * 1996-12-20 1998-07-02 Eli Lilly And Company Anti-obesity proteins
US20020019352A1 (en) * 1997-04-17 2002-02-14 David N. Brems Stable, active, human ob protein compositions and methods
EP0950417A3 (en) 1998-02-23 2000-02-23 Pfizer Products Inc. Treatment of skeletal disorders
AU3863699A (en) * 1998-04-20 1999-11-08 Mayo Foundation For Medical Education And Research Treatment of osteoporosis with leptin
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
EP1128840A1 (en) * 1998-10-27 2001-09-05 Eli Lilly And Company Prevention of muscle mass loss with leptin receptor ligands
AU781460B2 (en) * 1999-02-12 2005-05-26 Amgen, Inc. Glycosylated leptin compositions and related methods
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
AU2002359288B2 (en) 2001-10-22 2008-07-31 Amgen, Inc. Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment
JP3813152B2 (ja) 2002-03-12 2006-08-23 メルク エンド カムパニー インコーポレーテッド 置換アミド類
CA2571292C (en) * 2004-06-30 2013-05-21 Nektar Therapeutics Al, Corporation Polymer-factor ix moiety conjugates
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
CN101094689B (zh) 2004-11-01 2013-06-12 安米林药品有限责任公司 治疗肥胖以及肥胖相关疾病和病症的方法
WO2008048691A2 (en) * 2006-10-18 2008-04-24 Amylin Pharmaceuticals, Inc. Use of leptin for treating post-lipectomy ectopic fat deposition and other post-lipectomy associated disorders
WO2009149379A2 (en) 2008-06-05 2009-12-10 Regents Of The University Of Michigan Use of leptin for the treatment of fatty liver diseases and conditions
PT2621515T (pt) 2010-09-28 2017-07-12 Aegerion Pharmaceuticals Inc Polipéptido quimérico de leptina de foca-ser humano com solubilidade aumentada
RS58010B1 (sr) 2012-09-27 2019-02-28 Childrens Medical Ct Corp Jedinjenja za lečenje gojaznosti i postupci za njihovu upotrebu
PT3074033T (pt) 2013-11-26 2019-02-08 Childrens Medical Ct Corp Compostos para o tratamento de obesidade e métodos de utilização dos mesmos
US20170209408A1 (en) 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
HUE063647T2 (hu) 2016-09-12 2024-01-28 Amryt Pharmaceuticals Inc Eljárások anti-leptin semlegesítõ antitestek detektálására

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1228925B (it) * 1987-08-07 1991-07-10 Eniricerche Spa Procedimento per la preparazione dell'ormone della crescita umano
DK173142B1 (da) * 1988-08-24 2000-02-07 Natinco Nv Fremgangsmåde til forbedring af kødkvaliteten og foderomsætningseffektiviteten for grise
US5028440A (en) * 1990-01-30 1991-07-02 Iowa State University Research Foundation, Inc. Method of raising meat producing animals to increase lean tissue development
CA2169351A1 (en) * 1993-08-13 1995-02-23 Martin Wanner Process and device for treating the surface of large objects
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound
PT866720E (pt) * 1995-11-22 2004-06-30 Amgen Inc Proteina ob para aumentar a massa do tecido mole
IL124831A0 (en) * 1995-12-27 1999-01-26 Genentech Inc Ob protein derivatives having prolonged half-life
CA2275183A1 (en) * 1996-12-20 1998-07-02 Amgen Inc. Ob fusion protein compositions and methods
ATE223229T1 (de) * 1997-04-17 2002-09-15 Amgen Inc Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren

Also Published As

Publication number Publication date
IL127926A (en) 2006-08-20
EP0866720A1 (en) 1998-09-30
AU763755B2 (en) 2003-07-31
ATE259243T1 (de) 2004-02-15
IL127926A0 (en) 1999-11-30
ATE455554T1 (de) 2010-02-15
NZ527007A (en) 2005-01-28
NZ512083A (en) 2003-02-28
EP1285664B1 (en) 2010-01-20
EP0866720B1 (en) 2004-02-11
CA2358862A1 (en) 1997-05-29
PT866720E (pt) 2004-06-30
AU7607496A (en) 1997-06-11
ZA969605B (en) 1997-06-02
NZ511617A (en) 2003-08-29
EP0956862A1 (en) 1999-11-17
AU763769B2 (en) 2003-07-31
JP4173914B2 (ja) 2008-10-29
WO1997018833A1 (en) 1997-05-29
ES2339846T3 (es) 2010-05-26
DE69631544T2 (de) 2004-12-23
JP4227325B2 (ja) 2009-02-18
IL124442A0 (en) 1998-12-06
EP1285664A2 (en) 2003-02-26
ES2217327T3 (es) 2004-11-01
AU4265300A (en) 2000-09-07
DE69638119D1 (de) 2010-03-11
CA2236163A1 (en) 1997-05-29
JP2000500492A (ja) 2000-01-18
MX9803992A (es) 1998-09-30
JP2002206000A (ja) 2002-07-23
SI0866720T1 (en) 2004-10-31
AU4265200A (en) 2000-09-21
DE69631544D1 (de) 2004-03-18
EP1285664A3 (en) 2003-07-30

Similar Documents

Publication Publication Date Title
DK0866720T3 (da) OB-protein til forögelse af mager kropsmasse
IL148079A0 (en) Human ctla-4 antibodies and compositions containing the same
DE69733247D1 (de) Humanisiertes grünes-fluoreszenzprotein und methoden
ATE378403T1 (de) Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern
EA200300464A1 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ
DE3750342D1 (de) Menschliches gamma-interferon-spezifisches Rezeptorprotein, Antikörper gegen dieses Protein, Verfahren zur Herstellung dieses Proteins und dieses Antikörpers und dieses Protein und diesen Antikörper enthaltende Zusammensetzungen.
EA200000819A1 (ru) Остеоимплантат и способ его изготовления
DE68927697D1 (de) Fluor substituierte Benzocycloheptapyridine, Zusammensetzungen und Verfahren zur Verwendung derselben als antihistaminische Verbindungen
EA200000196A1 (ru) Универсальная плазма крови
DK0845943T3 (da) Nye peptider afledt fra humant heat shock protein 60 til behandling af diabetes, sammensætninger, fremgangsmåder og kits
DE69939068D1 (de) Entfernbare implantierbare medizinische leitung
DE69737651D1 (de) Cortistatin: neuropeptide, zusammensetzungen und methoden
DE69735039D1 (de) Acetylhydrolase des Plättchen aktivierenden Faktors, und entsprechendes Gen
DE69328060D1 (de) Angiotensin-II Typ-1 Rezeptor und dessen Herstellung
DK0972520T3 (da) Frysetörret sammensætning af humant, knoglemorfogenetisk protein MP52
SE9803962D0 (sv) Nucleic acid encoding a nervous tissue sodium channel
ES2175842T3 (es) Antagonistas de kv2.1.
EP1191096A4 (en) NEW PROTEIN AND ITS DNA
EP1467207A4 (en) Screening method
AU8499501A (en) Slo2 and slo4, novel potassium channel proteins from human brain
ATE336503T1 (de) Cyclophilin als allergen identifiziert
FI956041A0 (fi) Kompositiot ja diagnostiset menetelmät, joissa käytetään monoklonaalisia vasta-aineita CD44V6 vastaan